<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39340109</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>21</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Antibody Persistence and Risk of COVID-19 Infection: Insights from Modeling.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1079</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12091079</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In this post hoc exploratory study of the APHP-COVIBOOST trial (NCT05124171), we used statistical modeling to describe the evolution of neutralizing antibody (nAb) titers over time, asses its impact on SARS-CoV-2 infection, and explore potential differences between three booster vaccine formulations (D614, B.1.351, and BNT162b2).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Antibody titers were measured for 208 adult participants at day 28, 3 months, and 6 months using a microneutralization assay against different Omicron subvariants. We developed four specific Bayesian statistical models based on a core model, accounting for vaccine-specific antibody decline, boosting of nAb for breakthrough infection, and risk of infection according to nAb levels. The model findings were cross-verified using another validated microneutralization assay.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The decrease in nAb titers was significantly lower for the B.1.351 vaccine than for the other booster formulations. An inverse relationship was found between risk of infection upon exposure and nAb levels. With Omicron BA.1 data, these results translated into a positive relative vaccine efficacy against any infection over 6 months for the B.1.351 vaccine compared to the BNT162b2 (31%) and D614 (21%) vaccines.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Risk of infection decreased with increasing nAb titers for all vaccines. Statistical models predicted significantly better antibody persistence for the B.1.351 booster formulation compared to the other evaluated vaccines.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Coudeville</LastName><ForeName>Laurent</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Global Medical, Vaccines, 69007 Sanofi Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Konate</LastName><ForeName>Eleine</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Assistance Publique Hôpitaux de Paris (APHP), Hôpital Cochin, CIC Cochin Pasteur, Inserm, 75014 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simon</LastName><ForeName>Tabassome</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Sorbonne Université, Department of Clinical Pharmacology and Clinical Research Platform (URC-CRC-CRB), 75012 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Lamballerie</LastName><ForeName>Xavier</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Aix-Marseille University, IRD-Inserm-IRBA, 13005 Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patterson</LastName><ForeName>Scott</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Biostatistics Department, Sanofi Vaccines, Swiftwater, PA 18370, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>El Guerche-Séblain</LastName><ForeName>Clotilde</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-0196-4357</Identifier><AffiliationInfo><Affiliation>Global Medical, Vaccines, 69007 Sanofi Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Launay</LastName><ForeName>Odile</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Assistance Publique Hôpitaux de Paris (APHP), Hôpital Cochin, CIC Cochin Pasteur, Inserm, 75014 Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Université Paris Cité; Inserm, I-REIVAC, French Clinical Research Infrastructure Network (F-CRIN), 75014 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>AP-PH COVIBOOST Vaccine Trial Group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">antibody persistence</Keyword><Keyword MajorTopicYN="N">correlates of protection</Keyword><Keyword MajorTopicYN="N">neutralizing antibody titer</Keyword><Keyword MajorTopicYN="N">statistical modeling</Keyword></KeywordList><CoiStatement>L.C., S.P., and C.E.G.-S. are Sanofi employees and may hold stocks/shares in the company. O.L. reports a grant from the French Ministry of Health and grants or contracts from Pfizer, Sanofi-Pasteur, GlaxoSmithKline, MSD, MD, AstraZeneca, and Johnson &amp; Johnson. T.S. reports research grant support (through the institution) from Novartis, Sanofi, Merck, AstraZeneca, Lilly, Daichy Sankyo, GlaxoSmithKline, and French Ministry of Health and speaker or consulting honoraria (e.g., DSMB, Advisory Board, and Educational Events) from Ablative Solutions, Air Liquide, AstraZeneca, Sanofi, Servier, Novartis, and 4Living Biotech.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39340109</ArticleId><ArticleId IdType="pmc">PMC11435888</ArticleId><ArticleId IdType="doi">10.3390/vaccines12091079</ArticleId><ArticleId IdType="pii">vaccines12091079</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization . COVID-19 Weekly Epidemiological Update: 24 November 2023. WHO; Geneva, Switzerland: 2023. pp. 1–25.</Citation></Reference><Reference><Citation>WHO Coronavirus (COVID-19) Dashboard.  [(accessed on 11 December 2023)].  Available online:  https://covid19.who.int/</Citation></Reference><Reference><Citation>World Health Organization . COVID-19 Weekly Epidemiological Update: 20 July 2023. WHO; Geneva, Switzerland: 2023. pp. 1–15.</Citation></Reference><Reference><Citation>Fernandes Q., Inchakalody V.P., Merhi M., Mestiri S., Taib N., Moustafa Abo El-Ella D., Bedhiafi T., Raza A., Al-Zaidan L., Mohsen M.O., et al. Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines. Ann. Med. 2022;54:524–540. doi: 10.1080/07853890.2022.2031274.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07853890.2022.2031274</ArticleId><ArticleId IdType="pmc">PMC8843115</ArticleId><ArticleId IdType="pubmed">35132910</ArticleId></ArticleIdList></Reference><Reference><Citation>Arashiro T., Arima Y., Muraoka H., Sato A., Oba K., Uehara Y., Arioka H., Yanai H., Kuramochi J., Ihara G., et al. Coronavirus Disease 19 (COVID-19) Vaccine Effectiveness Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection During Delta-Dominant and Omicron-Dominant Periods in Japan: A Multicenter Prospective Case-control Study (Factors Associated with SARS-CoV-2 Infection and the Effectiveness of COVID-19 Vaccines Study) Clin. Infect. Dis. 2023;76:e108–e115. doi: 10.1093/cid/ciac635.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac635</ArticleId><ArticleId IdType="pmc">PMC9384625</ArticleId><ArticleId IdType="pubmed">35918782</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert P.B., Donis R.O., Koup R.A., Fong Y., Plotkin S.A., Follmann D. A COVID-19 Milestone Attained—A Correlate of Protection for Vaccines. N. Engl. J. Med. 2022;387:2203–2206. doi: 10.1056/NEJMp2211314.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMp2211314</ArticleId><ArticleId IdType="pubmed">36507702</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry J., Osman S., Wright J., Richard-Greenblatt M., Buchan S.A., Sadarangani M., Bolotin S. Does a humoral correlate of protection exist for SARS-CoV-2? A systematic review. PLoS ONE. 2022;17:e0266852. doi: 10.1371/journal.pone.0266852.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0266852</ArticleId><ArticleId IdType="pmc">PMC8993021</ArticleId><ArticleId IdType="pubmed">35395052</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng S., Phillips D.J., White T., Sayal H., Aley P.K., Bibi S., Dold C., Fuskova M., Gilbert S.C., Hirsch I., et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat. Med. 2021;27:2032–2040. doi: 10.1038/s41591-021-01540-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01540-1</ArticleId><ArticleId IdType="pmc">PMC8604724</ArticleId><ArticleId IdType="pubmed">34588689</ArticleId></ArticleIdList></Reference><Reference><Citation>Fong Y., Huang Y., Benkeser D., Carpp L.N., Áñez G., Woo W., McGarry A., Dunkle L.M., Cho I., Houchens C.R., et al. Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial. Nat. Commun. 2023;14:331. doi: 10.1038/s41467-022-35768-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-35768-3</ArticleId><ArticleId IdType="pmc">PMC9851580</ArticleId><ArticleId IdType="pubmed">36658109</ArticleId></ArticleIdList></Reference><Reference><Citation>Fong Y., McDermott A.B., Benkeser D., Roels S., Stieh D.J., Vandebosch A., Le Gars M., Van Roey G.A., Houchens C.R., Martins K., et al. Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial. Nat. Microbiol. 2022;7:1996–2010. doi: 10.1038/s41564-022-01262-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-022-01262-1</ArticleId><ArticleId IdType="pmc">PMC10166187</ArticleId><ArticleId IdType="pubmed">36357712</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert P.B., Montefiori D.C., McDermott A.B., Fong Y., Benkeser D., Deng W., Zhou H., Houchens C.R., Martins K., Jayashankar L., et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science. 2022;375:43–50. doi: 10.1126/science.abm3425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abm3425</ArticleId><ArticleId IdType="pmc">PMC9017870</ArticleId><ArticleId IdType="pubmed">34812653</ArticleId></ArticleIdList></Reference><Reference><Citation>Launay O., Cachanado M., Luong Nguyen L.B., Ninove L., Lachâtre M., Ben Ghezala I., Bardou M., Schmidt-Mutter C., Lacombe K., Laine F., et al. Immunogenicity and Safety of Beta-Adjuvanted Recombinant Booster Vaccine. N. Engl. J. Med. 2022;387:374–376. doi: 10.1056/NEJMc2206711.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2206711</ArticleId><ArticleId IdType="pmc">PMC9258749</ArticleId><ArticleId IdType="pubmed">35767474</ArticleId></ArticleIdList></Reference><Reference><Citation>Launay T., Konate E., Cachanado M., Lachatre M., Ghezala I.B., Lacombe K., Laine F., Schmidt-Mutter C., de Lamballerie X., Simon T. Persistence of neutralizing antibodies induced by recombinant protein vaccine SARS-CoV-2 Omicron variants strain B1.531; Proceedings of the Journées Nationales D’infectiologie (JNI) 2023; Grenoble, France. 7–9 June 2023.</Citation></Reference><Reference><Citation>Launay O., Gupta R., Machabert T., Konate E., Rousseau A., Claire V., Beckers F., Chicz R., Botelho-Nevers E., Cachanado M., et al. Beta-variant recombinant SARS-CoV-2 vaccine induces durable cross-reactive antibodies against Omicron variants. Res. Sq. (Prepr. Version 1) 2023 doi: 10.21203/rs.3.rs-2513105/v1.</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.3.rs-2513105/v1</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallian P., Pastorino B., Morel P., Chiaroni J., Ninove L., de Lamballerie X. Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood donors. Antiviral Res. 2020;181:104880. doi: 10.1016/j.antiviral.2020.104880.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2020.104880</ArticleId><ArticleId IdType="pmc">PMC7362788</ArticleId><ArticleId IdType="pubmed">32679056</ArticleId></ArticleIdList></Reference><Reference><Citation>Nurtop E., Villarroel P.M.S., Pastorino B., Ninove L., Drexler J.F., Roca Y., Gake B., Dubot-Peres A., Grard G., Peyrefitte C., et al. Combination of ELISA screening and seroneutralisation tests to expedite Zika virus seroprevalence studies. Virol. J. 2018;15:192. doi: 10.1186/s12985-018-1105-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-018-1105-5</ArticleId><ArticleId IdType="pmc">PMC6307276</ArticleId><ArticleId IdType="pubmed">30587193</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y., Borisov O., Kee J.J., Carpp L.N., Wrin T., Cai S., Sarzotti-Kelsoe M., McDanal C., Eaton A., Pajon R., et al. Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation. Sci. Rep. 2021;11:23921. doi: 10.1038/s41598-021-03154-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-03154-6</ArticleId><ArticleId IdType="pmc">PMC8671391</ArticleId><ArticleId IdType="pubmed">34907214</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaslow D.C. Force of infection: A determinant of vaccine efficacy? npj Vaccines. 2021;6:51. doi: 10.1038/s41541-021-00316-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-021-00316-5</ArticleId><ArticleId IdType="pmc">PMC8042006</ArticleId><ArticleId IdType="pubmed">33846340</ArticleId></ArticleIdList></Reference><Reference><Citation>Stan Development Team  RStan: The R Interface to Stan. R Package; Version 2.21.2; Stan Development Team, 202.  [(accessed on 11 December 2023)].  Available online:  http://mc-stan.org/</Citation></Reference><Reference><Citation>Vehtari A., Gelman A., Gabry J. Practical Bayesian model evaluation using leave-one-out cross-validation and WAIC. Stat. Comput. 2017;27:1413–1432. doi: 10.1007/s11222-016-9696-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11222-016-9696-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Coudeville L., Bailleux F., Riche B., Megas F., Andre P., Ecochard R. Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: Development and application of a bayesian random-effects model. BMC Med. Res. Methodol. 2010;10:18. doi: 10.1186/1471-2288-10-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2288-10-18</ArticleId><ArticleId IdType="pmc">PMC2851702</ArticleId><ArticleId IdType="pubmed">20210985</ArticleId></ArticleIdList></Reference><Reference><Citation>Desai K., Coudeville L., Bailleux F. Modelling the long-term persistence of neutralizing antibody in adults after one dose of live attenuated Japanese encephalitis chimeric virus vaccine. Vaccine. 2012;30:2510–2515. doi: 10.1016/j.vaccine.2012.02.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.02.005</ArticleId><ArticleId IdType="pubmed">22342547</ArticleId></ArticleIdList></Reference><Reference><Citation>López E.L., Contrini M.M., Mistchenko A., Kieffer A., Baggaley R.F., Di Tanna G.L., Desai K., Rasuli A., Armoni J. Modeling the long-term persistence of hepatitis A antibody after a two-dose vaccination schedule in Argentinean children. Pediatr. Infect. Dis. J. 2015;34:417–425. doi: 10.1097/INF.0000000000000605.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000000605</ArticleId><ArticleId IdType="pubmed">25764099</ArticleId></ArticleIdList></Reference><Reference><Citation>Michos A., Tatsi E.B., Filippatos F., Dellis C., Koukou D., Efthymiou V., Kastrinelli E., Mantzou A., Syriopoulou V. Association of total and neutralizing SARS-CoV-2 spike -receptor binding domain antibodies with epidemiological and clinical characteristics after immunization with the 1(st) and 2(nd) doses of the BNT162b2 vaccine. Vaccine. 2021;39:5963–5967. doi: 10.1016/j.vaccine.2021.07.067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.07.067</ArticleId><ArticleId IdType="pmc">PMC8302834</ArticleId><ArticleId IdType="pubmed">34400017</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>